Shots:
- Insilico has entered into a drug discovery collaboration with Eli Lilly to accelerate the discovery & development of novel therapeutics across multiple therapeutic areas using Insilico’s Pharma.AI
- As per the deal, Lilly will gain exclusive global rights to develop, manufacture & commercialize Insilico’s preclinical oral candidates for select indications. Also, both will collaborate on multiple R&D programs focused on targets selected by Lilly using Pharma.AI
- In exchange, Insilico will receive $115M upfront, along with development, regulatory, & commercial milestones, representing the total deal value up to $2.75B, plus tiered royalties on future sales
Ref: PRnewswire | Image: Eli Lilly & Insilico | Press Release
Related News: Insilico Medicine Expands AI-Driven CNS Collaboration with Tenacia in a ~$94.75M Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
